farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2023.182farmaec-953Research ArticleREVIEW ARTICLESОБЗОРНЫЕ ПУБЛИКАЦИИOncoprotective effects of chondroprotectors: glucosamine, chondroitin sulfate and undenatured type II collagenОб онкопротективных эффектах хондропротекторов: глюкозамина, хондроитина сульфата и неденатурированного коллагена II типаhttps://orcid.org/0000-0002-2659-7998ТоршинИ. Ю.TorshinI. Yu.

Торшин Иван Юрьевич – к.ф-м.н., к.х.н., ведущий научный сотрудник

WoS ResearcherID: C-7683-2018; Scopus Author ID: 7003300274 

ул. Вавилова, д. 44, корп. 2, Москва 119333, Россия 

Ivan Yu. Torshin – PhD (Phys. Math.), PhD (Chem.), Leading Researcher

WoS ResearcherID: C-7683-2018; Scopus Author ID:  7003300274 

 44 corp. 2 Vavilov Str., Moscow 119333, Russia 

https://orcid.org/0000-0002-5070-5450ЧучалинА. Г.ChuchalinA. G.

Чучалин Александр Григорьевич – д.м.н., профессор, академик РАН, заведующий кафедрой госпитальной терапии педиатрического факультета

ул. Островитянова, д. 1, Москва 117997, Россия 

Aleksandr G. Chuchalin – Dr. Med. Sc., Professor, Academician of RAS, Pulmonologist, Head of Chair of Hospital Therapy, Faculty of Pediatrics

1 Ostrovityanov Str., Moscow 117997, Russia 

https://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.

Громова Ольга Алексеевна – д.м.н., профессор, ведущий научный сотрудник

WoS ResearcherID: J-4946-2017; Scopus Author ID: 7003589812 

ул. Вавилова, д. 44, корп. 2, Москва 119333, Россия 

Olga A. Gromova – Dr. Med. Sc., Professor, Leading Researcher

WoS ResearcherID: J-4946-2017; Scopus Author ID:  7003589812 

 44 corp. 2 Vavilov Str., Moscow 119333, Russia 

unesco.gromova@gmail.comФедеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center “Computer Science and Control”, RASRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияPirogov Russian National Research Medical UniversityRussian Federation202312122023164681699Copyright © Torshin I.Y., Chuchalin A.G., Gromova O.A., 20242024Торшин И.Ю., Чучалин А.Г., Громова О.А.Torshin I.Y., Chuchalin A.G., Gromova O.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/953

Objective: to systematize fundamental, clinical, and epidemiological data on the oncoprotective effects of chondroprotectors: chondroitin sulfate (CS), glucosamine (including glucosamine sulfate, GS), and undenatured type II collagen (UC-II).Material and methods. A systematic computer analysis of 6176 publications on the relationship between CS/GS/UC-II and tumor diseases found by the query “(glucosamine OR chondroitin OR ((“Collagen Type II” OR “type II collagen”) AND pharmacology)) AND (Cancer OR cancers OR tumor OR tumors OR tumors OR tumour*) NOT tumor necrosis)” in PubMed and Embase databases was performed. All articles of any format from 1900 to the present day with full available abstracts were taken. A topological approach to data analysis was used.Results. Large-scale clinical and epidemiological studies and meta-analyses showed that regular consumption of CS/GS reduced the risk of colorectal cancer and lung cancer, as well as mortality from tumor diseases. The mechanisms of oncoprotective action of CS/GS are through inhibition of the pro-inflammatory cascade of tumor necrosis factor alpha, CD44 receptor and nuclear factor kappa B, and initiation of tumor cell apoptosis. By modulating the CD44 receptor and specific O-glycosylation of intracellular proteins, GS inhibits the pro-inflammatory effects of arachidonic acid cascade, interleukins IL-6, IL-8, the PI3K/Akt proliferative pathway, and cyclin-dependent kinases. The first postgenomic studies of CS/GS oncoprotective effects, including microbiome studies, was performed. Additionally, CS contributes to the inhibition of the effects of vascular endothelial growth factor and matrix metalloproteinases involved in tumor metastasis and invasion. Potentially, CS/GS oncoprotective effects may be enhanced by the anti-inflammatory effect of UC-II: the addition of NC-II substance to CS/GS complex makes it possible to reduce the autoimmune branch of pathogenesis not only in primary, but also in secondary OA and rheumatoid arthritis.Conclusion. The CS and glucosamine (including GS) chondroprotectors exhibit oncoprotective effects. The use of CS and GS together with UС-II standardized pharmaceutical forms can enhance their anti-inflammatory and immunomodulatory effects.

Цель: систематизация фундаментальных, клинических и эпидемиологических данных об онкопротективном действии хондропротекторов хондроитина сульфата (ХС), глюкозамина (в т.ч. глюкозамина сульфата, ГС) и неденатурированного коллагена II типа (НК-II).Материал и методы. Проведен систематический компьютерный анализ 6176 публикаций по взаимосвязи ХС/ГС/НК-II и опухолевых заболеваний, найденных по запросу «(glucosamine OR chondroitin OR ((“Collagen Type II” OR “type II collagen”) AND pharmacology)) AND (Cancer OR cancers OR tumor OR tumors OR tumour*) NOT tumor necrosis» в базах данных PubMed и Embase. Были взяты все статьи любого формата с 1900 г. по настоящее время, для которых имелись полные абстракты. Использован топологический подход к анализу данных.Результаты. Крупномасштабные клинико-эпидемиологические исследования и метаанализы показали, что регулярное употребление ХС/ГС снижает риск развития рака толстой кишки и рака легких, а также смертности от опухолевых заболеваний. Механизмы онкопротективного действия ХС/ГС осуществляются путем ингибирования провоспалительного каскада фактора некроза опухоли альфа, рецептора CD44 и ядерного фактора каппа B, а также инициации апоптоза опухолевых клеток. Модулируя рецептор CD44 и специфическое O-гликозилирование внутриклеточных белков, ГС ингибирует провоспалительные эффекты каскада арахидоновой кислоты, интерлейкинов ИЛ-6, ИЛ-8, пролиферативного пути PI3K/Akt, циклинзависимых киназ. Проведены первые постгеномные исследования онкопротективных эффектов ХС/ГС, включая исследования микробиома. Дополнительно ХС способствует ингибированию эффектов фактора роста эндотелия сосудов и матриксных металлопротеиназ, участвующих в метастазировании и инвазии опухолей. Потенциально онкопротективные эффекты ХС/ГС могут усиливаться противовоспалительным действием НК-II: добавление в комплексе ХС/ГС вещества НК-II позволяет снижать аутоиммунную ветвь патогенеза не только при первичном, но и при вторичном ОА, ревматоидном артрите.Заключение. Хондропротекторы ХС и глюкозамин (в т.ч. ГС) проявляют онкопротективные эффекты. Применение ХС и ГС совместно со стандартизированными фармацевтическими формами НК-II может усиливать их противовоспалительное и иммуномодулирующее действие.

Опухолевые заболеваниянутрициологияанализ больших данныхХондрогардТРИОTumor diseasenutritional sciencebig data analyticsChondroguardTRIOReferencesMellai M., Casalone C., Corona C., et al. Chondroitin sulphate proteoglycans in the tumour microenvironment. Adv Exp Med Biol. 2020; 1272: 73–92. https://doi.org/10.1007/978-3-030-48457-6_5.Mellai M., Casalone C., Corona C., et al. Chondroitin sulphate proteoglycans in the tumour microenvironment. Adv Exp Med Biol. 2020; 1272: 73–92. https://doi.org/10.1007/978-3-030-48457-6_5.Торшин И.Ю., Лила А.М., Загородний Н.В. и др. Разработка верифицированной шкалы риска остеоартрита на основе кросс-секционного исследования клинико-анамнестических параметров и фармакологического анамнеза пациентов. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2023; 16 (1): 70–9. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.158.Torshin I.Yu., Lila А.М., Zagorodniy N.V., et al. Development of a verified osteoarthritis risk scale based on a crosssectional study of clinical and anamnestic parameters and pharmacological anamnesis of patients. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023; 16 (1): 70–9 (in Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.158.Громова О.А., Торшин И.Ю., Лила А.М., Громов А.Н. Молекулярные механизмы глюкозамина сульфата при лечении дегенеративно-дистрофических заболеваний суставов и позвоночника: результаты протеомного анализа. Неврология, нейропсихиатрия, психосоматика. 2018; 10 (2): 38–44. https://doi.org/10.14412/2074-2711-2018-2-38-44.Gromova O.A., Torshin I.Yu., Lila A.M., Gromov A.N. Molecular mechanisms of action of glucosamine sulfate in the treatment of degenerative-dystrophic diseases of the joints and spine: results of proteomic analysis. Neurology, Neuropsychiatry, Psychosomatics. 2018; 10 (2): 38–44 (in Russ.). https://doi.org/10.14412/2074-2711-2018-2-38-44.Quastel J., Cantero A. Inhibition of tumour growth by D-glucosamine. Nature. 1953; 171 (4345): 252–4. https://doi.org/10.1038/171252a0.Quastel J., Cantero A. Inhibition of tumour growth by D-glucosamine. Nature. 1953; 171 (4345): 252–4. https://doi.org/10.1038/171252a0.Sorkin E., Fjelde A. The effect of D-glucosamine and related products on human cancer cells in tissue culture. G Ital Chemioter. 1956; 3 (3–4): 355–61.Sorkin E., Fjelde A. The effect of D-glucosamine and related products on human cancer cells in tissue culture. G Ital Chemioter. 1956; 3 (3–4): 355–61.Luhrs W. A contribution to the question glucosamine on the growth retardation of tumours. Acta Unio Int Contra Cancrum. 1957; 13 (3): 480–1.Luhrs W. A contribution to the question glucosamine on the growth retardation of tumours. Acta Unio Int Contra Cancrum. 1957; 13 (3): 480–1.Громова О.А., Торшин И.Ю., Лила А.М. и др. Дифференциальный хемореактомный анализ глюкозамина сульфата и нестероидных противовоспалительных препаратов: перспективные синергичные комбинации. Современная ревматология. 2018; 12 (2): 36–43. https://doi.org/10.14412/1996-7012-2018-2-36-43.Gromova O.A., Torshin I.Yu., Lila A.M., et al. Differential chemoreactome analysis of glucosamine sulfate and non-steroidal antiinflammatory drugs: promising synergistic drug combinations. Modern Rheumatology Journal. 2018; 12 (2): 36–43 (in Russ.). https://doi.org/10.14412/1996-7012-2018-2-36-43.Торшин И.Ю., Громова О.А., Лила А.М. и др. Результаты постгеномного анализа молекулы глюкозамина сульфата указывают на перспективы лечения коморбидных заболеваний. Современная ревматология. 2018; 12 (4): 129–36. https://doi.org/10.14412/1996-7012-2018-4-129-136.Torshin I.Yu., Gromova O.A., Lila A.M., et al. The results of postgenomic analysis of a glucosamine sulfate molecule indicate the prospects of treatment for comorbidities. Modern Rheumatology Journal. 2018; 12 (4): 129–36 (in Russ.). https://doi.org/10.14412/1996-7012-2018-4-129-136.Kantor E.D., O'Connell K., Liang P.S., et al. Glucosamine use and risk of colorectal cancer: results from UK biobank. Cancer Epidemiol Biomarkers Prev. 2022; 31 (3): 647–53. https://doi.org/10.1158/1055-9965.EPI-21-1171.Kantor E.D., O'Connell K., Liang P.S., et al. Glucosamine use and risk of colorectal cancer: results from UK biobank. Cancer Epidemiol Biomarkers Prev. 2022; 31 (3): 647–53. https://doi.org/10.1158/1055-9965.EPI-21-1171.Liu B., Yang W., Zhang K. Role of glucosamine and chondroitin in the prevention of cancer: a meta-analysis. Nutr Cancer. 2023; 75 (3): 785–94. https://doi.org/10.1080/01635581.2023.2173258.Liu B., Yang W., Zhang K. Role of glucosamine and chondroitin in the prevention of cancer: a meta-analysis. Nutr Cancer. 2023; 75 (3): 785–94. https://doi.org/10.1080/01635581.2023.2173258.Громова О.А., Торшин И.Ю., Лила А.М., Шавловская О.А. О перспективах использования неденатурированного коллагена II типа в терапии остеоартрита и других заболеваний суставов. Современная ревматология. 2022; 16 (4): 111–6. https://doi.org/10.14412/1996-7012-2022-4-111-116.Gromova O.A., Torshin I.Yu., Lila A.M., Shavlovskaya O.A. On the prospects for the use of undenatured type II collagen in the treatment of osteoarthritis and other joint diseases. Modern Rheumatology Journal. 2022; 16 (4): 111–6 (in Russ.). https://doi.org/10.14412/1996-7012-2022-4-111-116.Torshin I.Yu., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: Metric approach within the framework of the theory of classification of feature values. Pattern Recognit Imag Anal. 2017; 27 (2): 184–99. https://doi.org/10.1134/S1054661817020110.Torshin I.Yu., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: Metric approach within the framework of the theory of classification of feature values. Pattern Recognit Imag Anal. 2017; 27 (2): 184–99. https://doi.org/10.1134/S1054661817020110.Рудаков К.В., Торшин И.Ю. Об отборе информативных значений признаков на базе критериев разрешимости в задаче распознавания вторичной структуры белка. Доклады Академии наук. 2011; 441 (1): 24–8.Rudakov K.V., Torshin I.Yu. Selection of informative feature values on the basis of solvability criteria in the problem of protein secondary structure recognition. Doklady AkademiI Nauk. 2011; 441 (1): 24–8 (in Russ.).Torshin I.Y., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 1: Factorization approach. Pattern Recog Image Anal. 2017; 27 (1): 16–28. https://doi.org/10.1134/S1054661817010151.Torshin I.Y., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 1: Factorization approach. Pattern Recog Image Anal. 2017; 27 (1): 16–28. https://doi.org/10.1134/S1054661817010151.Торшин И.Ю., Громова О.А. 25 мгновений молекулярной фармакологии. О развитии клинико-фармакологического мышления. Иваново: А-Гриф; 2012: 684 с.Torshin I.Yu., Gromova O.A. 25 moments of molecular pharmacology. On the development of clinical and pharmacological thinking. Ivanovo: A-Grif; 2012: 684 pp. (in Russ.).Wu R., Shang N., Gui M., et al. Sturgeon (acipenser)-derived chondroitin sulfate suppresses human colon cancer HCT-116 both in vitro and in vivo by inhibiting proliferation and inducing apoptosis. Nutrients. 2020; 12 (4): 1130. https://doi.org/10.3390/nu12041130.Wu R., Shang N., Gui M., et al. Sturgeon (acipenser)-derived chondroitin sulfate suppresses human colon cancer HCT-116 both in vitro and in vivo by inhibiting proliferation and inducing apoptosis. Nutrients. 2020; 12 (4): 1130. https://doi.org/10.3390/nu12041130.Wang J., Zhao W., Chen H., et al. Anti-tumor study of chondroitin sulfate-methotrexate nanogels. Nanoscale Res Lett. 2017; 12 (1): 572. https://doi.org/10.1186/s11671-017-2324-1.Wang J., Zhao W., Chen H., et al. Anti-tumor study of chondroitin sulfate-methotrexate nanogels. Nanoscale Res Lett. 2017; 12 (1): 572. https://doi.org/10.1186/s11671-017-2324-1.Shi X., Yang X., Liu M., et al. Chondroitin sulfate-based nanoparticles for enhanced chemo-photodynamic therapy overcoming multidrug resistance and lung metastasis of breast cancer. Carbohydr Polym. 2021; 254: 117459. https://doi.org/10.1016/j.carbpol.2020.117459.Shi X., Yang X., Liu M., et al. Chondroitin sulfate-based nanoparticles for enhanced chemo-photodynamic therapy overcoming multidrug resistance and lung metastasis of breast cancer. Carbohydr Polym. 2021; 254: 117459. https://doi.org/10.1016/j.carbpol.2020.117459.Rivlin M., Navon G. Glucosamine and N-acetyl glucosamine as new CEST MRI agents for molecular imaging of tumors. Sci Rep. 2016; 6: 32648. https://doi.org/10.1038/srep32648.Rivlin M., Navon G. Glucosamine and N-acetyl glucosamine as new CEST MRI agents for molecular imaging of tumors. Sci Rep. 2016; 6: 32648. https://doi.org/10.1038/srep32648.Rivlin M., Anaby D., Nissan N., et al. Breast cancer imaging with glucosamine CEST (chemical exchange saturation transfer) MRI: first human experience. Eur Radiol. 2022; 32 (11): 7365–73. https://doi.org/10.1007/s00330-022-08772-w.Rivlin M., Anaby D., Nissan N., et al. Breast cancer imaging with glucosamine CEST (chemical exchange saturation transfer) MRI: first human experience. Eur Radiol. 2022; 32 (11): 7365–73. https://doi.org/10.1007/s00330-022-08772-w.Rani A., Baruah R., Goyal A. Prebiotic chondroitin sulfate disaccharide isolated from chicken keel bone exhibiting anticancer potential against human colon cancer cells. Nutr Cancer. 2019; 71 (5): 825–39. https://doi.org/10.1080/01635581.2018.1521446.Rani A., Baruah R., Goyal A. Prebiotic chondroitin sulfate disaccharide isolated from chicken keel bone exhibiting anticancer potential against human colon cancer cells. Nutr Cancer. 2019; 71 (5): 825–39. https://doi.org/10.1080/01635581.2018.1521446.Ferro M., Giuberti G., Zappavigna S., et al. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. Oncol Rep. 2012; 27 (2): 409–15. https://doi.org/10.3892/or.2011.1526.Ferro M., Giuberti G., Zappavigna S., et al. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. Oncol Rep. 2012; 27 (2): 409–15. https://doi.org/10.3892/or.2011.1526.Masuda S., Azuma K., Kurozumi S., et al. Anti-tumor properties of orally administered glucosamine and N-acetyl-D-glucosamine oligomers in a mouse model. Carbohydr Polym. 2014; 111: 783–7. https://doi.org/10.1016/j.carbpol.2014.04.102.Masuda S., Azuma K., Kurozumi S., et al. Anti-tumor properties of orally administered glucosamine and N-acetyl-D-glucosamine oligomers in a mouse model. Carbohydr Polym. 2014; 111: 783–7. https://doi.org/10.1016/j.carbpol.2014.04.102.Wu R., Li P., Wang Y., et al. Structural analysis and anti-cancer activity of low-molecular-weight chondroitin sulfate from hybrid sturgeon cartilage. Carbohydr Polym. 2022; 275: 118700. https://doi.org/10.1016/j.carbpol.2021.118700.Wu R., Li P., Wang Y., et al. Structural analysis and anti-cancer activity of low-molecular-weight chondroitin sulfate from hybrid sturgeon cartilage. Carbohydr Polym. 2022; 275: 118700. https://doi.org/10.1016/j.carbpol.2021.118700.Chou W.Y., Chuang K.H., Sun D., et al. Inhibition of PKC-induced COX-2 and IL-8 expression in human breast cancer cells by glucosamine. J Cell Physiol. 2015; 230 (9): 2240–51. https://doi.org/10.1002/jcp.24955.Chou W.Y., Chuang K.H., Sun D., et al. Inhibition of PKC-induced COX-2 and IL-8 expression in human breast cancer cells by glucosamine. J Cell Physiol. 2015; 230 (9): 2240–51. https://doi.org/10.1002/jcp.24955.Tsai C.Y., Lee T.S., Kou Y.R., Wu Y.L. Glucosamine inhibits IL-1betamediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009; 108 (2): 489–98. https://doi.org/10.1002/jcb.22278.Tsai C.Y., Lee T.S., Kou Y.R., Wu Y.L. Glucosamine inhibits IL-1betamediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009; 108 (2): 489–98. https://doi.org/10.1002/jcb.22278.Chesnokov V., Gong B., Sun C., Itakura K. Anti-cancer activity of glucosamine through inhibition of N-linked glycosylation. Cancer Cell Int. 2014; 14: 45. https://doi.org/10.1186/1475-2867-14-45.Chesnokov V., Gong B., Sun C., Itakura K. Anti-cancer activity of glucosamine through inhibition of N-linked glycosylation. Cancer Cell Int. 2014; 14: 45. https://doi.org/10.1186/1475-2867-14-45.Hosea R., Hardiany N.S., Ohneda O., Wanandi S.I. Glucosamine decreases the stemness of human ALDH(+) breast cancer stem cells by inactivating STAT3. Oncol Lett. 2018; 16 (4): 4737–44. https://doi.org/10.3892/ol.2018.9222.Hosea R., Hardiany N.S., Ohneda O., Wanandi S.I. Glucosamine decreases the stemness of human ALDH(+) breast cancer stem cells by inactivating STAT3. Oncol Lett. 2018; 16 (4): 4737–44. https://doi.org/10.3892/ol.2018.9222.Yu Z., Ju Y., Liu H. Antilung cancer effect of glucosamine by suppressing the phosphorylation of FOXO. Mol Med Rep. 2017; 16 (3): 3395–400. https://doi.org/10.3892/mmr.2017.6976.Yu Z., Ju Y., Liu H. Antilung cancer effect of glucosamine by suppressing the phosphorylation of FOXO. Mol Med Rep. 2017; 16 (3): 3395–400. https://doi.org/10.3892/mmr.2017.6976.Friedman S.J., Kimball T., Trotter C.D., Skehan P.J. The inhibition of thymidine kinase in glial tumor cells by an amino sugar, D-glucosamine. Cancer Res. 1977; 37 (4): 1068–74.Friedman S.J., Kimball T., Trotter C.D., Skehan P.J. The inhibition of thymidine kinase in glial tumor cells by an amino sugar, D-glucosamine. Cancer Res. 1977; 37 (4): 1068–74.Cocchiola R., Lopreiato M., Guazzo R., et al. The induction of Maspin expression by a glucosamine-derivative has an antiproliferative activity in prostate cancer cell lines. Chem Biol Interact. 2019; 300: 63–72. https://doi.org/10.1016/j.cbi.2019.01.014.Cocchiola R., Lopreiato M., Guazzo R., et al. The induction of Maspin expression by a glucosamine-derivative has an antiproliferative activity in prostate cancer cell lines. Chem Biol Interact. 2019; 300: 63–72. https://doi.org/10.1016/j.cbi.2019.01.014.Liu B.Q., Meng X., Li C., et al. Glucosamine induces cell death via proteasome inhibition in human ALVA41 prostate cancer cell. Exp Mol Med. 2011; 43 (9): 487–93. https://doi.org/10.3858/emm.2011.43.9.055.Liu B.Q., Meng X., Li C., et al. Glucosamine induces cell death via proteasome inhibition in human ALVA41 prostate cancer cell. Exp Mol Med. 2011; 43 (9): 487–93. https://doi.org/10.3858/emm.2011.43.9.055.Guo J., Hu J., Cao R., et al. Androgen receptor is inactivated and degraded in bladder cancer cells by phenyl glucosamine via miR-449a restoration. Med Sci Monit. 2018; 24: 2294–301. https://doi.org/10.12659/MSM.906836.Guo J., Hu J., Cao R., et al. Androgen receptor is inactivated and degraded in bladder cancer cells by phenyl glucosamine via miR-449a restoration. Med Sci Monit. 2018; 24: 2294–301. https://doi.org/10.12659/MSM.906836.Oh H.J., Lee J.S., Song D.K., et al. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. Biochem Biophys Res Commun. 2007; 360 (4): 840–5. https://doi.org/10.1016/j.bbrc.2007.06.137.Oh H.J., Lee J.S., Song D.K., et al. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. Biochem Biophys Res Commun. 2007; 360 (4): 840–5. https://doi.org/10.1016/j.bbrc.2007.06.137.Liang Y., Xu W., Liu S., et al. N-acetyl-glucosamine sensitizes nonsmall cell lung cancer cells to TRAIL-induced apoptosis by activating death receptor 5. Cell Physiol Biochem. 2018; 45 (5): 2054–70. https://doi.org/10.1159/000488042.Liang Y., Xu W., Liu S., et al. N-acetyl-glucosamine sensitizes nonsmall cell lung cancer cells to TRAIL-induced apoptosis by activating death receptor 5. Cell Physiol Biochem. 2018; 45 (5): 2054–70. https://doi.org/10.1159/000488042.Wang L.S., Chen S.J., Zhang J.F., et al. Anti-proliferative potential of glucosamine in renal cancer cells via inducing cell cycle arrest at G0/G1 phase. BMC Urol. 2017; 17 (1): 38. https://doi.org/10.1186/s12894-017-0221-7.Wang L.S., Chen S.J., Zhang J.F., et al. Anti-proliferative potential of glucosamine in renal cancer cells via inducing cell cycle arrest at G0/G1 phase. BMC Urol. 2017; 17 (1): 38. https://doi.org/10.1186/s12894-017-0221-7.Zhou Y., Li X., Morita Y., et al. Identification of the effects of chondroitin sulfate on inhibiting CDKs in colorectal cancer based on bioinformatic analysis and experimental validation. Front Oncol. 2021; 11: 705939. https://doi.org/10.3389/fonc.2021.705939.Zhou Y., Li X., Morita Y., et al. Identification of the effects of chondroitin sulfate on inhibiting CDKs in colorectal cancer based on bioinformatic analysis and experimental validation. Front Oncol. 2021; 11: 705939. https://doi.org/10.3389/fonc.2021.705939.Hwang M.S., Baek W.K. Glucosamine induces autophagic cell death through the stimulation of ER stress in human glioma cancer cells. Biochem Biophys Res Commun. 2010; 399 (1): 111–6. https://doi.org/10.1016/j.bbrc.2010.07.050.Hwang M.S., Baek W.K. Glucosamine induces autophagic cell death through the stimulation of ER stress in human glioma cancer cells. Biochem Biophys Res Commun. 2010; 399 (1): 111–6. https://doi.org/10.1016/j.bbrc.2010.07.050.Liu X., Liu Y., Hao J., et al. In vivo anti-cancer mechanism of lowmolecular-weight fucosylated chondroitin sulfate (LFCS) from sea cucumber Cucumaria frondosa. Molecules. 2016; 21 (5): 625. https://doi.org/10.3390/molecules21050625.Liu X., Liu Y., Hao J., et al. In vivo anti-cancer mechanism of lowmolecular-weight fucosylated chondroitin sulfate (LFCS) from sea cucumber Cucumaria frondosa. Molecules. 2016; 21 (5): 625. https://doi.org/10.3390/molecules21050625.Prinz R.D., Willis C.M., Viloria-Petit A., Kluppel M. Elimination of breast tumor-associated chondroitin sulfate promotes metastasis. Genet Mol Res. 2011; 10 (4): 3901–13. https://doi.org/10.4238/2011.December.8.9.Prinz R.D., Willis C.M., Viloria-Petit A., Kluppel M. Elimination of breast tumor-associated chondroitin sulfate promotes metastasis. Genet Mol Res. 2011; 10 (4): 3901–13. https://doi.org/10.4238/2011.December.8.9.Silver D.J., Siebzehnrubl F.A., Schildts M.J., et al. Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci. 2013; 33 (39): 15603–17. https://doi.org/10.1523/JNEUROSCI.3004-12.2013.Silver D.J., Siebzehnrubl F.A., Schildts M.J., et al. Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci. 2013; 33 (39): 15603–17. https://doi.org/10.1523/JNEUROSCI.3004-12.2013.Pudelko A., Wisowski G., Olczyk K., Kozma E.M. The dual role of the glycosaminoglycan chondroitin-6-sulfate in the development, progression and metastasis of cancer. FEBS J. 2019; 286 (10): 1815–37. https://doi.org/10.1111/febs.14748.Pudelko A., Wisowski G., Olczyk K., Kozma E.M. The dual role of the glycosaminoglycan chondroitin-6-sulfate in the development, progression and metastasis of cancer. FEBS J. 2019; 286 (10): 1815–37. https://doi.org/10.1111/febs.14748.Willis C.M., Kluppel M. Chondroitin sulfate-E is a negative regulator of a pro-tumorigenic Wnt/beta-catenin-Collagen 1 axis in breast cancer cells. PLoS One. 2014; 9 (8): e103966. https://doi.org/10.1371/journal.pone.0103966.Willis C.M., Kluppel M. Chondroitin sulfate-E is a negative regulator of a pro-tumorigenic Wnt/beta-catenin-Collagen 1 axis in breast cancer cells. PLoS One. 2014; 9 (8): e103966. https://doi.org/10.1371/journal.pone.0103966.Торшин И.Ю., Громова О.А., Лила А.М. и др. Таргетное действие глюкозамина сульфата при сочетании остеоартрита и опухолевой патологии. Русский медицинский журнал. 2019; 6: 23–30.Torshin I.Yu., Gromova O.A., Lila A.M., et al. The targeted effect of glucosamine sulfate in the combination of osteoarthritis and tumor pathology. Russian Medical Journal. 2019; 6: 23–30 (in Russ.).Wu R., Shen Q., Li G., et al. The regulatory network of sturgeon chondroitin sulfate on colorectal cancer inhibition by transcriptomic and proteomic analysis. Int J Mol Sci. 2021; 22 (17): 9395. https://doi.org/10.3390/ijms22179395.Wu R., Shen Q., Li G., et al. The regulatory network of sturgeon chondroitin sulfate on colorectal cancer inhibition by transcriptomic and proteomic analysis. Int J Mol Sci. 2021; 22 (17): 9395. https://doi.org/10.3390/ijms22179395.Wu R., Shen Q., Li P., Shang N. Sturgeon chondroitin sulfate restores the balance of gut microbiota in colorectal cancer bearing mice. Int J Mol Sci. 2022; 23 (7): 3723. https://doi.org/10.3390/ijms23073723.Wu R., Shen Q., Li P., Shang N. Sturgeon chondroitin sulfate restores the balance of gut microbiota in colorectal cancer bearing mice. Int J Mol Sci. 2022; 23 (7): 3723. https://doi.org/10.3390/ijms23073723.Громова О.А., Торшин И.Ю., Наумов А.В., Максимов В.А. Хемомикробиомный анализ глюкозамина сульфата, пребиотиков и нестероидных противовоспалительных препаратов. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (3): 270–82. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.049.Gromova O.A., Torshin I.Yu., Naumov A.V., Maksimov V.A. Chemomicrobiomic analysis of glucosamine sulfate, prebiotics and non-steroidal anti-inflammatory drugs. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (3): 270–82 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.049.Kantor E.D., Newton C.C., Giovannucci E.L., et al. Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control. 2018; 29 (3): 389–97. https://doi.org/10.1007/s10552-018-1003-6.Kantor E.D., Newton C.C., Giovannucci E.L., et al. Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control. 2018; 29 (3): 389–97. https://doi.org/10.1007/s10552-018-1003-6.Li G., Zhang X., Liu Y., et al. Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. Eur Respir J. 2022; 59 (3): 2101399. https://doi.org/10.1183/13993003.01399-2021.Li G., Zhang X., Liu Y., et al. Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. Eur Respir J. 2022; 59 (3): 2101399. https://doi.org/10.1183/13993003.01399-2021.Kantor E.D., Zhang X., Wu K., et al. Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: results from the Nurses' Health Study and Health Professionals follow-up study. Int J Cancer. 2016; 139 (9): 1949–57. https://doi.org/10.1002/ijc.30250.Kantor E.D., Zhang X., Wu K., et al. Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: results from the Nurses' Health Study and Health Professionals follow-up study. Int J Cancer. 2016; 139 (9): 1949–57. https://doi.org/10.1002/ijc.30250.Zhou J., Wu Z., Lin Z., et al. Association between glucosamine use and cancer mortality: a large prospective cohort study. Front Nutr. 2022; 9: 947818. https://doi.org/10.3389/fnut.2022.947818.Zhou J., Wu Z., Lin Z., et al. Association between glucosamine use and cancer mortality: a large prospective cohort study. Front Nutr. 2022; 9: 947818. https://doi.org/10.3389/fnut.2022.947818.Yoshinari O., Marone P.A., Moriyama H., et al. Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen. Toxicol Mech Methods. 2013; 23 (7): 491–9. https://doi.org/10.3109/15376516.2013.781255.Yoshinari O., Marone P.A., Moriyama H., et al. Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen. Toxicol Mech Methods. 2013; 23 (7): 491–9. https://doi.org/10.3109/15376516.2013.781255.Seo M.C., Kim S., Kim S.H., et al. Discoidin domain receptor 1 mediates collagen-induced inflammatory activation of microglia in culture. J Neurosci Res. 2008; 86 (5): 1087–95. https://doi.org/10.1002/jnr.21552.Seo M.C., Kim S., Kim S.H., et al. Discoidin domain receptor 1 mediates collagen-induced inflammatory activation of microglia in culture. J Neurosci Res. 2008; 86 (5): 1087–95. https://doi.org/10.1002/jnr.21552.Sahin K., Kucuk O., Orhan C., et al. Niacinamide and undenatured type II collagen modulates the inflammatory response in rats with monoiodoacetate-induced osteoarthritis. Sci Rep. 2021; 11 (1): 14724. https://doi.org/10.1038/s41598-021-94142-3Sahin K., Kucuk O., Orhan C., et al. Niacinamide and undenatured type II collagen modulates the inflammatory response in rats with monoiodoacetate-induced osteoarthritis. Sci Rep. 2021; 11 (1): 14724. https://doi.org/10.1038/s41598-021-94142-3.

The authors declare that there are no conflicts of interest present.